Ono Pharmaceutical (ON40) Stock Overview
Produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
ON40 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4.58 |
| 52 Week High | JP¥4.58 |
| 52 Week Low | JP¥3.10 |
| Beta | 0.044 |
| 1 Month Change | 16.84% |
| 3 Month Change | 32.37% |
| 1 Year Change | 37.13% |
| 3 Year Change | -32.08% |
| 5 Year Change | n/a |
| Change since IPO | -41.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| ON40 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 14.5% | -4.5% | 0.7% |
| 1Y | 37.1% | 16.6% | 6.7% |
Return vs Industry: ON40 exceeded the German Pharmaceuticals industry which returned 18.7% over the past year.
Return vs Market: ON40 exceeded the German Market which returned 8.7% over the past year.
Price Volatility
| ON40 volatility | |
|---|---|
| ON40 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: ON40 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ON40's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 4,287 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| ON40 fundamental statistics | |
|---|---|
| Market cap | €6.26b |
| Earnings (TTM) | €337.28m |
| Revenue (TTM) | €2.75b |
Is ON40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ON40 income statement (TTM) | |
|---|---|
| Revenue | JP¥509.35b |
| Cost of Revenue | JP¥153.89b |
| Gross Profit | JP¥355.45b |
| Other Expenses | JP¥293.05b |
| Earnings | JP¥62.40b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 132.80 |
| Gross Margin | 69.79% |
| Net Profit Margin | 12.25% |
| Debt/Equity Ratio | 13.5% |
How did ON40 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 17:40 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ono Pharmaceutical Co., Ltd. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |